Previous 10 | Next 10 |
IGMS develops IgM antibodies targeting cancer. The science is neat, however, trial results published at the last two ASH conferences didn't impress investors. The company has a short cash runway of 3-4 quarters at most. For further details see: IGM Biosciences: Interesti...
IGM Biosciences (NASDAQ:IGMS) announced upcoming milestones for the company’s early-stage trials for IGM-6268, an investigational monoclonal antibody, being developed as a treatment or prophylaxis for mild to moderate COVID-19. In Phase 1 clinical trial conducted in the U.S., the first...
– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – – IGM-6268 Phase 1 clinical trials advancing in U.S. and South Africa – ...
MOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Gug...
MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40t...
IGM Biosciences (IGMS -1.8%) is set to continue its losing streak for the sixth consecutive session after H.C. Wainwright slashed the price target for the stock citing “underwhelming” data for IGM-2323, the company’s experimental therapy for B-cell malignancies. According...
Gainers: Nuverra Environmental Solutions (NYSE:NES) +88%. Arena (NASDAQ:ARNA) +82%. BELLUS (NASDAQ:BLU) +56%. Foghorn Therapeutics (NASDAQ:FHTX) +43%. Petros Pharmaceuticals (NASDAQ:PTPI) +45%. Biofrontera (NASDAQ:BFRI) +29%. Mawson Infrastructure Group (OTCQB:MIGI) +17%. Reliance Global Grou...
Gainers: Arena Pharmaceuticals (NASDAQ:ARNA) +84%, BELLUS Health (NASDAQ:BLU) +68%, Foghorn Therapeutics (NASDAQ:FHTX) +37%, Petros Pharmaceuticals (NASDAQ:PTPI) +27%, Tabula Rasa HealthCare (NASDAQ:TRHC) +23%. Losers: IGM Biosciences (NASDAQ:IGMS)...
- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile - - Phase 2 Clinical Trials in DLBCL and FL and Combination Clinical Trials to be Initiated - ...
IGM Biosciences (NASDAQ:IGMS) has announced a grant agreement with the Bill & Melinda Gates Foundation to fund the studies aimed at treatments for the prevention of malaria. The mosquito-borne disease causes more than 400,000 deaths annually, with over 200M cases across the globe, accordi...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...